The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2022 | Reverse fate mapping of CAR-T cells in patients with large B-cell lymphoma
In this video, Zinaida Good, PhD, Stanford University, Stanford, CA, discusses reverse fate mapping of CAR-T cells in patients with large B-cell lymphoma and the importance of understanding how CAR-T cells change on the clonal level. Dr Good explains that because CAR-T therapy is extremely successful in large B-cell lymphoma, it is important to further analyze gene expression in CAR-T cells and see how this information can help researchers better understand which clones are likely to be more successful during treatment. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
